NCT04273061View on ClinicalTrials.gov

Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity

PHASE2RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

June 17, 2020

Primary Completion Date

October 31, 2027

Study Completion Date

October 31, 2027

Conditions
Breast CancerLung CancerGastrointestinal CancerGenitourinary CancerGynecologic CancerSarcomaUnknown Primary TumorsHead and Neck CancerSkin Cancer
Interventions
DRUG

Atezolizumab

1200 mg by intravenous infusion every 3 weeks as tolerated

Trial Locations (2)

V5Z 4E6

RECRUITING

BC Cancer, Vancouver

M5G 2M9

WITHDRAWN

University Health Network / Princess Margaret Cancer Centre, Toronto

All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

lead

British Columbia Cancer Agency

OTHER